Investors are eager to hear more about the biotech's experimental cancer treatments.
Compare ONTX Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Onconova Therapeutics
A $25 billion buyout, a long-awaited FDA approval, two positive clinical studies, and one biopharma losing 37% of its value, are this week's top biotech stories.
Which health-care stocks experienced the agony of defeat this week?
Onconova Therapeutics reported disappointing phase 3 results for high-risk myelodysplastic syndrome drug rigosertib. Is this sell-off a buying opportunity or a reason to leave and not turn back?
The long-awaited move from the Federal Reserve to cut back on its quantitative easing sent the markets roaring higher, but among the few decliners today, Jabil Circuit dropped almost 21%, Onconova Therapeutics fell 19%, and Gogo declined 16%. Find out why these stocks didn't join in the Fed-induced celebration Wednesday.
Onconova discontinues a late-stage trial for its lead experimental drug. Is this a classic overreaction by emotional traders or a reason to avoid Onconova?
Onconova, Enzymotec, DepoMed, and Omeros could make health care headlines this morning. Here’s why.